O
Origene Technologies
50,000 Primary Antibodies - 90,000 ORF cDNA clones | OriGene
About Origene Technologies
OriGene Technologies, Inc. operates in the biotechnology sector, providing a wide range of gene-based research tools and reagents. The company serves academic, pharmaceutical, and biotech researchers by offering products such as cDNA clones, antibodies, proteins, RNAi, and lentiviral particles. OriGene's business model is centered on the production and distribution of high-quality research reagents, leveraging a large inventory and a distributed manufacturing chain to ensure timely delivery. Revenue is generated through the direct sale of these products to research institutions and companies worldwide. The company is known for its extensive catalog, which includes over 37,000 human full-length ORF cDNA clones, 50,000 primary antibodies, and 10,000 human proteins, among other research tools. OriGene also provides educational resources such as videos, webinars, and scientific posters to support the research community.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1996
- Headquarters
- Rockville, United States
- Employees
- 128
- Open positions
- None listed
- Dealroom signal
- 42.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
- Investment activity
- 4 companies, latest Oct 2015
- Capital deployed
- $6.9M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2015 | $17M | $68M | Mérieux Equity Partners · IDG Capital · Cathay Capital | — |
| SERIES COther financing | Mar 2013 | $21M | $85M | Accel · Kleiner Perkins · Qiming Venture Partners | — |
Growth signals
Latest recorded traffic for Origene Technologies is 130K monthly website visits, down 7.1% over the last three months. Origene Technologies's team grew 4.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Acris AntibodiesHerford, GermanyAcris took over responsibility for marketing the DPC Biermann research products, mostly antibodies
→
Genetron HealthDongcheng District, ChinaSpecializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment
$103Mvaluation
BB
Beijing Zhongshan Golden Bridge BiotechnologyDongcheng District, ChinaBeijing Zhongshan Golden Bridge Biotechnology operates as a Pathology Reagent Company
→
Blue Heron BiotechnologyBothell, United StatesYour Gene Synthesis Company - Your Genome Editing Company | Blue Heron Bio
$15Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A5 investors entered at this stage
Accel- SESBI & TH Venture Capital Enterprise
Morningside- ZCZero2IPO Capital
- PCPresident International Development Corporation
Series B and later5 investors entered at this stage
Kleiner Perkins
Qiming Venture Partners
Mérieux Equity Partners
IDG Capital
Cathay Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Origene Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Origene Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.